TLX Telix Pharmaceuticals Limited

Price Chart

Executive Summary

Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable tolerability with standard-of-care combinations and no new safety signals. The data support advancing to Part 2 randomized expansion, with FDA engagement underway for U.S. enrollment. This is a positive clinical milestone for a first-in-class rADC candidate, but the stock impact is tempered by early-stage data and no near-term approval catalyst.

Actionable Insight

Key Facts

• Part 1 data from 36 patients showed acceptable safety across all SoC combination cohorts (abiraterone, enzalutamide, docetaxel) with no new safety signals.
• All 36 patients received both doses of TLX591-Tx per protocol; hematologic events (Grade 3-4 thrombocytopenia/neutropenia) were transient and consistent with class profile.
• Dosimetry showed radiation exposure to key organs well below established safety limits; highest absorbed dose in liver (1.62-5.08 mGy/MBq), low salivary gland uptake (0.001-0.104 mGy/MBq).
• Part 2 randomized 2:1 expansion is actively dosing in Australia, New Zealand, Canada, Turkey, UK, with approvals in China, Singapore, South Korea; FDA engagement underway for U.S. IND amendment.
• TLX591-Tx is a first-in-class lutetium rADC with differentiated pharmacology (liver clearance, minimal kidney/salivary toxicity) vs. existing PSMA-targeted small molecule RLTs.

Financial Impact

No financial data provided; TLX591-Tx has not received marketing authorization in any jurisdiction.

Risk Factors

• Part 2 randomized data (n~490) may not replicate Part 1 safety profile or show efficacy benefit vs. SoC alone.
• Regulatory delays in U.S. IND amendment could slow enrollment and timeline.
• Competition from approved PSMA-targeted RLTs (e.g., Pluvicto) with established commercial presence.

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status